Protocols: BU’s Outterson helms $350M antibiotics project; Adaptimmune lands on EMA’s inside track
Kevin Outterson of Boston University’s School of Law has been tapped to run the new CARB-X program, a $350 million, public/private project that will bring together partners on both sides of the Atlantic to spur the preclinical development of new antibiotics. HHS is providing $30 million to help fund the effort in its first year. Growing resistance to antibiotics has steadily raised the threat posed by new superbugs now in circulation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.